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Abstract
Background: Genomic technology can now deliver cost effective, targeted
diagnosis and treatment for patients. Genetic counselling is a communica-
tion process empowering patients and families to make autonomous deci-
sions and effectively use new genetic information. The skills of genetic
counselling and expertise of genetic counsellors are integral to the effective
implementation of genomic medicine.
Sources of data: Original papers, reviews, guidelines, policy papers and
web-resources.
Areas of agreement: An international consensus on the deﬁnition of gen-
etic counselling. Genetic counselling is necessary for implementation of
genomic medicine.
Areas of controversy: Models of genetic counselling.
Growing points: Genomic medicine is a growing and strategic priority for
many health care systems. Genetic counselling is part of this.
Areas timely for developing research: An evidence base is necessary,
incorporating implementation and outcome research, to enable health care
systems, practitioners, patients and families to maximize the utility (medic-
ally and psychologically) of the new genomic possibilities.
Key words: genetic counselling, genetic counsellors, genomic medicine, policy, practice
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Introduction
The focus and title of the UK Chief medical ofﬁcers
2016 report ‘Generation Genome’, emphasizes the
importance currently placed on developments in
genomic medicine.1 Advances in genomic technol-
ogy will deliver data at affordable scale and has the
potential to deliver cost effective targeted diagnosis
and treatment.
The drive towards the vision of genomic medi-
cine is informed by various large-scale sequencing
projects across the world. One of the UK 100,000
Genome Project’s aims is to transform the National
Health Service by integrating genomics into main-
stream clinical care.2 The opportunities and chal-
lenges identiﬁed for genomic medicine 10 years
after the publication of the ﬁrst draft of the Human
Genome Sequence3 have been borne out in the
experience of the 100,000 Genomes Project and the
other projects internationally. There are many chal-
lenges ahead, to name but a few, these include: con-
troversies around data use and sharing across
international borders, the need for standardized
methods for interpretation of genomic data, the
streamlining of reliable quality-assured results deliv-
ery within a clinical setting, maximized clinical util-
ity of results while minimizing the uncertainty of
the information and managing uncertainty about
which data to return in the clinical setting. However,
learning from existing clinical services, the UK
100,000 Genomes Project and other similar projects
are already enabling genomic diagnoses to be deliv-
ered within health care settings.2,4
Traditionally, genetic testing and genetic coun-
selling within the UK has taken place within NHS
regional genetics centres in tertiary care. The focus
has been predominantly on rare syndromes and disor-
ders showing Mendelian inheritance patterns. Genetic
counsellors work as part of the multidisciplinary
health care team providing expertise both in the sci-
ence of genetics as well as facilitating the inevitable
inter-generational (and often emotional) conversations
from the psychological impact of the science. There is
an ongoing debate as to the tasks of genetic counsel-
ling in this traditional domain and the developing roles
in relation to genomic medicine.5–8
‘Genetic counsellor’ is an internationally recog-
nized professional title with practitioners having
specialist education, assessed competencies in genet-
ics (and now genomics) combined with counselling
skills.6,9,10 In England, as part of the workforce
development initiated through the investment in the
development of genomic medicine, the NHS scien-
tist training programme offers a genomic counsel-
ling branch to equip practitioners to work under
the current professional title of genetic counsellor.
This is a new addition to existing routes into prac-
tice in the UK which have been provided through
master’s level training followed by a competency
based assessment and registration with the Genetic
Counsellor Registration Board. The ongoing demand
for a skilled and competent workforce will require a
variety of routes for health care practitioners to
develop relevant skills.
It is probable that all health care practitioners
will be engaging with genomic medicine in time and
as it is ‘mainstreamed’ at scale, health professionals
will increasingly be asked to communicate and man-
age the results from genomic testing. The question is
how much of what they will be doing is simply ‘hav-
ing a conversation based on genomic data’ versus
applying some aspects of genetic counselling skills
and practice, i.e. will all health professionals be
‘doing’ genetic counselling to some degree? The pro-
fessional bodies representing genetic counsellors are
in a strong position to guide this to resolution. As
yet it is unknown what, of genetic counselling skills
and theory, will and should be translated into main-
stream practice.5,6
There is a growing market in genetic tests avail-
able directly to the consumer and both the American
College of Medical Genetics and the European
Society for Human Genetics have recommended that
genetic counselling is made available to online custo-
mers. This is further discussed in a recent position
paper11 and will not form the focus of this review.
In this review the developments in and chal-
lenges for genetic counselling, both as an activity
and a profession, will be discussed in relation to
genomic medicine, but focussed on practice within
health care settings.
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Sources of data
A structured search of Web of Science, PubMed,
Embase and CINAHL was conducted using the search
terms ‘genetic counselling’ and ‘genomic medicine’.
Articles were included if they presented empiric data
or detailed discussion on the practice of genetic coun-
selling in health care settings. They were excluded if
they referred solely to healthy population genome
sequencing studies, sequencing in a research setting or
direct to consumer or commercial genetic testing.
Bibliographies were scanned to retrieve additional rele-
vant articles and policy documents. The websites from
Professional Societies relevant to genetic counselling
practice in Europe, North America and Australasia
were reviewed for applicable policy documents. The
summaries below offer an overview of the issues repre-
sented in published material. However, this is not a
systematic review, and the topics selected for presenta-
tion are guided by the experience of the two authors.
Our aim is to reﬂect on the climate of genomic medi-
cine, view this through a genetic counsellor lens and
articulate the issues of importance to genetic counsel-
ling practise.
Findings
Genetic counselling
There is consensus among professional bodies around
the world that the act of genetic counselling is a
client-centred communication process with the aim of
helping patients understand, adapt and adjust to the
medical or psychosocial consequences of genetic con-
tributions to disease.12 Deﬁnitions of genetic counsel-
ling have evolved over time, however professionals
trained in genetic counselling traditionally have assessed
an individual’s risk of a genetic disorder, prepared indi-
viduals for genetic testing, communicated the results
and assisted the management of the patients’ genetic dis-
ease as well as preparing and supporting the individual
to contact their relatives also at risk of the same disease.
Patients would attend genetic services either to obtain a
diagnosis of a genetic condition or because they knew
of a condition in their family and wanted to understand
their own options and choices for managing the conse-
quences of the condition.
There is long history of conceptualizing genetic
counselling as teaching and counselling or more
recently a very circumscribed form of psychother-
apy.6,13 In the era of genomic medicine the debate
as to where to focus expertise continues.
Genetic/genomic counselling and genomic
medicine
In discussions of the implications of genomic medi-
cine, the term ‘genomic counselling’ has started to
be used. It is unclear how this is differentiated from
the act of genetic counselling but it is related to the
developments in technology and the desire to create
genomic medicine deﬁned by the National Human
Genome Research Institute as:
an emerging medical discipline that involves
using genomic information about an individual
as part of their clinical care (e.g. for diagnostic
or therapeutic decision-making) and the health
outcomes and policy implications of that clinical
use.
The earliest use of the term ‘genomic medicine’ was
in the title of a Commentary paper, in 2009. Here
the argument was made that information from a
whole genome should be part of an integrated elec-
tronic health record. The implication being that
genomic data would be available for use across
health services in all medical specialities. The whole
clinical team would be involved in using this data in
the management of patients.14 We now know that
much of the relevance, across clinical specialities,
will be using molecular testing for screening, diag-
nosis and to guide treatment15 and thus genomic
medicine will eventually become simply ‘medicine’.
The focus on technology and data in deﬁnitions of
genomic medicine is important but there should
also be a recognition of how the information gener-
ated is incorporated into the lives, experiences and
health care decisions of individuals.
The challenges relating to storing, interpreting
and using data generated from genome sequencing
are well rehearsed and remain.16,17 How to commu-
nicate and make decisions about ‘secondary’, ‘inci-
dental’ or ‘additional ﬁndings’ are also an active
3Genetic counselling in the era of genomic medicine, 2018
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area of discussion.18 The terminology around these
ﬁndings is used inconsistently but broadly they
relate to results within the sequence that are found
or searched for deliberately, that are secondary to
the reason for doing the sequence to start with.
There is also a confusion between issues relating to
sequencing technologies used in: (a) a clinical set-
ting as a technology to answer a clinical question
with return of results related to that clinical ques-
tion, (b) sequencing used in a healthy population
with the intention of returning clinically actionable
results and (c) sequencing used for research cohorts
with the possibility of returning ‘results’ to partici-
pants (including raw sequence data). The response
to these challenges will depend on the context
within which the technology is being used.
Genetic counsellors have skills enabling them to
be involved in all stages of the patient’s pathway
through genomic medicine, however there is uncer-
tainty, as genetic technologies become more rou-
tinely used in health care, what aspects of their
practice is necessary and at which time points. It is
probable that as genomic medicine becomes main-
stream, certain roles that are currently considered
as an integral part of genetic counselling practice,
may become part of other clinicians’ roles (Fig. 1).
Consent for genomic testing
Historically clinical genetics services were the only
healthcare setting where genetic testing could be
accessed. Now, genomic technologies can be accessed
across the entire healthcare service. Given the exten-
sive experience in working with genetic technologies,
clinical genetics services have developed systems for
patient management that may be applicable within
non-genetics specialisms. One of these systems relates
to the process of consent. The ability to offer pre-
symptomatic testing for inherited diseases such as
Huntington’s Disease in the 1990s resulted in the rec-
ommendation for multi-session counselling prior to
taking blood for analysis, thus giving the patient time
to psychologically adapt and prepare for a possible
future condition where there was no effective treat-
ment or cure.19 The two pre-testing counselling ses-
sions focused on information giving about the disease
and the genetic risks and exploration of how the
patient would incorporate their potential new genetic
status into their lives, once they had the results. The
aim was to facilitate an informed decision about
whether to have the test, who should be tested and
when the test should be performed and also to
address the emotional context of the test decision.
This took into account the presence of a highly pene-
trant single gene disorder, concerns about the history
of genetics and incorporated the values of autonomy
and non-directiveness into the genetic counselling
approach.
As more presymptomatic/predictive testing has
been possible for conditions where prevention or
management strategies can be recommended, such
as cancer predisposition genes, genetic counselling
protocols have been shortened. However there is
still an emphasis on provision of information and
decision making about the test exploring the emo-
tional and psychosocial implications.20,21 As genetic
technologies become incorporated into more rou-
tine health care decision-making about treatment
and management they will become a routine part of
diagnostics. It may be that in this context, less focus
is placed on the decision about whether to have the
test, with a shift to more exploration, post-test as to
what the results mean. The consent conversation
then moves – where the main body of information
about the genetic test result occurs post-test as
opposed to pre-test. Once a genetic result is known
there becomes a need to have a conversation about
the relevance of this to treatment and clinical deci-
sion making within the pathway of resolving a med-
ical issue, rather than a personal decision about the
desirability and consequences of obtaining genetic
information. However, the pre-test information for
at-risk relatives, who do not currently have genetic
disease, is still as relevant as it ever was and would
likely fall within the domain of existing genetic
counselling practice. Thus, the care of ‘at risk rela-
tives’, who are not yet unwell, but who are poten-
tially pre-disposed to developing disease, should be
referred by primary and secondary care, into ter-
tiary genetics services.
Genetic counsellors have speciﬁc training and
skills in communication and genetic science but are
4 C. Patch and A. Middleton, 2018
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Previous care pathway: phenotype to genotype
A 23 year old woman is referred to clinical genecs as her mother died in her fores of 
breast cancer when the young woman was a teenager. The genec counsellor takes a family 
history which demonstrates a number of relaves who developed breast cancer in their 30s 
and an aunt who has ovarian cancer. The paent talks about the grief she sll feels about 
her mother’s death and the fear she has of geng cancer. The genec counsellor supports 
the paent as she expresses her fears and explains that if genec tesng were to become 
possible, a sample would be needed from a living relave who has had breast or ovarian 
cancer. The paent is encouraged to talk with her aunt and ﬁnd out if she is willing to have 
genec tesng as, given the family history, there is a greater than 10% prior probability of a 
pathogenic BRCA1 or BRCA2 variant being found. Tesng (sequencing of BRCA1 and 2) is 
completed and a BRCA1 disease causing variant is idenﬁed in the aunt; at a separate 
genec counselling appointment the aunt expresses a sense of responsibility for the result 
but is also relieved that pre-symptomac, predicve tesng is now possible for the younger 
generaon, including her 23 year old niece. 
Genec counselling in this case involves management of the whole family, including risk 
assessment, preparing for diagnosc and then predicve tesng and helping both the 
paent, her aunt and other relaves manage the emoonal context of what cancer means 
to them. 
Here, it is the phenotype of cancer in the family history that determines what genes should 
be tested. The genotype discovered via genec tesng ﬁts neatly with the phenotype 
presented; thus when predicve genec tesng is oﬀered to (currently) healthy, at-risk 
relaves, when the pathogenic variant is discovered there is conﬁdence that this is clearly 
linked to an increased lifeme risk of developing breast and ovarian cancer. At risk relaves 
can then take preventave steps to manage future disease. 
Immediate/future pathway: genotype to phenotype
A woman aged 50 is diagnosed with breast cancer. As part of the somac sequencing of her 
tumour, the pathology report indicates the possibility of a germline pathogenic variant in 
BRCA1, the breast surgeon requests a conﬁrmaon via a separate blood sample from the 
woman. This indeed conﬁrms her BRCA1 germline status, thus suggesng that her breast 
cancer could have been caused by this. This result determines her treatment pathway; 
surgical and chemotherapy opons. However, aside from her own breast cancer, she has no 
relevant family history of either breast or ovarian cancer in relaves (and she has lots of 
women in her family who are healthy in old age). Thus, the ‘family history phenotype’ is not 
typical of a BRCA1 paern and therefore it is diﬃcult to know how predicve the 
pathogenic variant could be in relaves. Of course, if every member of the family is oﬀered 
genec tesng for the same BRCA1 variant, then it would be possible to see if those healthy 
relaves do not have the same variant, but this is not praccally possible. 
The woman is oﬀered genec counselling aer she has ﬁnished her cancer treatment to 
discuss the implicaons for her own future cancer risks and the risks for her daughter. Her 
daughter aends and is surprised to ﬁnd out that it is not possible to be completely certain 
about her own risk of breast and ovarian cancer. Apart from her mother who is now 
recovering well, she has no experience of family members having cancer and in the past has 
had no worries about developing cancer. Genec counselling in this case might focus on 
managing the unexpectedness and uncertainty of the genec result and supporng 
decisions about predicve tesng and cascading informaon about the result through the 
family. Genec counselling could also cover the opons in terms of screening and 
preventave measures for at risk relaves (these will involve a careful balancing of 
uncertain, but raised risk of disease and will be guided by how the paent perceives this 
risks). 
In this case the genotype revealed via tesng aempts to predict the phenotype of cancer in 
the family, but given that there is no exisng phenotype (i.e. many aﬀected people at a 
young age) it is diﬃcult to know if there are modifying eﬀects on the behaviour of the 
genotype (e.g. addional as yet unidenﬁed modiﬁer genes or environmental eﬀects). This 
uncertain risk proﬁle means that the genec counselling will focus on helping the daughter 
and rest of the family make sense of the newly discovered genotype; and help them to 
make decisions about their own health based on this informaon. 
Fig. 1 Previous and future care pathways involving genetic counselling.
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a scarce resource. There is a tension developing in
where to focus this resource and a need for an evi-
dence base to determine what is best practice and
what competencies and skills are required for the
health professionals who are responsible for the
delivery of genomic health care.
The availability of increasingly extensive genetic
analyses has raised the possibility of more uncertain
ﬁndings and ﬁndings unrelated to the reason for
requesting the test. Concern is expressed as to how
to ensure appropriate consent for sequencing ana-
lysis in various contexts, how to manage the uncer-
tainty of the interpretation of the data and how to
communicate that uncertainty back to patients.4,22,23
Questions have arisen as to how information about
these possible outcomes should be incorporated into
the consent process and how to ensure that consent
is appropriate.24 In 2013 the American College of
Medical Genetics created some controversy by sug-
gesting that all patients receiving genome sequencing
should have an analyses performed to identify
actionable genetic variants in a speciﬁc list of genes
linked to serious, life-threatening disease. These
guidelines have recently been updated with a process
for nominating new genes.25 The recommendation is
that the patient can choose to opt-out of receiving
these secondary ﬁndings. Other policy statements
concerning the clinical use of whole genome tech-
nologies, recommend minimizing the chance of gen-
erating secondary ﬁndings by performing clinically
directed tests.26 In the UK 100,000 Genomes Project
the decision has been made to limit the possible add-
itional ﬁndings that will be analysed.2
The complexities of decisions about testing and
informational requirements have focused genetic coun-
selling activity at the beginning of the patient pathway
through the genetic testing process. The provision of
more detailed information and more choices regarding
results has been explored in the context of research
studies, where results from sequencing have been
returned in the healthy populations and in participants
recruited from health care services. Various studies
have also explored different ways of presenting infor-
mation and eliciting preferences for the return of add-
itional ﬁndings and results.27–29 Such research offers
helpful exploration for the mechanisms that could be
applied to clinical pathways. Recent empirical work
interviewing health care professionals consenting
patients for genomic testing has reiterated that being
informed about all possible outcomes of genetic testing
is not possible and moreover may not always reﬂect
appropriate consent.30 The time taken for this
detailed consenting process has also been identiﬁed
as a problematic issue.31 Given the extensive experi-
ence that genetic counsellors have developed over the
years in consenting patients for genetic testing, their
insight offers a valuable contribution to new practi-
tioners of genomic medicine. The consent conversa-
tion for a genomic test is multi-faceted. It should
cover: the implications of the result, both for the
individual patient and also their family (with a recog-
nition that patients are expected to inform their rela-
tives about their result so that they can seek out their
own testing where relevant); the types of result that
may come back from the laboratory (i.e. pathogenic,
uncertain or benign) and what each of these will
mean in terms of future risk and disease management
and plans for genomic data storage, protection and
sharing.
New roles for genetic counsellors
As the technologies used for genetic testing have
increased in complexity, genetic counsellors have
become involved in new roles. The global number
of genetic counsellors is estimated at only 7000,
practising in at least 28 countries with over 60% in
North America. In North America, Canada and
South Africa genetic counsellors are increasingly
employed by laboratories. A recent survey identiﬁed
the main roles as customer liaison/case coordination
and variant interpretation/result reporting.32 A sur-
vey in Europe, prior to setting up the genetic counsel-
ling European Registration system, did not identify
practitioners working is this role yet.33 In Europe and
the UK, as discussed previously, most genetic counsel-
lors work in multidisciplinary teams within the set-
ting of specialist genetic health care. The teams
include medically qualiﬁed clinical geneticist and
laboratory scientists. Emerging models of genomic
medicine emphasize the iterative nature of variant
interpretation with input from the bioinformatician,
6 C. Patch and A. Middleton, 2018
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the laboratory scientist and the clinician.18 These
multidisciplinary teams will often now include a gen-
etic counsellor.34,35
Understanding of genome sequencing technolo-
gies and variant interpretation is identiﬁed as an
important part of the knowledge of genetic counsel-
lors and other health professionals. With increasing
volumes of sequencing data there are a plethora of
bioinformatics tools being developed which curate
and synthesize evidence for variant classiﬁcation in
line with professional guidelines.36 It is probable
that these bioinformatics tools will become more
sophisticated over time and remove the need for as
much human intervention as there is today.
In addition to having roles within laboratories, as
well as multidisciplinary genetics teams, genetic coun-
sellors are now moving further aﬁeld. Genetic coun-
sellors, will often practise autonomously within
non-genetics specialisms, for example, joining the spe-
cialist ophthalmology, cancer, endocrine, ENT or
dermatology clinic. With the mainstreaming of gen-
omic medicine they are now being called upon to
train and educate their non-genetics colleagues in
genomics. Increasingly genetic counsellors also offer
their own independent private practice, in the UK
this is happening already within the cancer and pre-
implantation genetic diagnosis ﬁeld. They also may
practice full time as academics in education or research
as well as policy and industry.5
Increasingly these roles are being developed inde-
pendently of the tertiary genetic services in a similar
way to the autonomous roles that have developed
in other countries for example in North America.
As noted above although numbers are small, genetic
counsellors practice across both developed and
developing countries. How models of care will be
implemented is unclear and the mainstreaming conver-
sation includes all members of the health care team.
International networks and opportunities for sharing
expertise, learning and good practice are growing in
genetic counselling, nursing and midwifery and medi-
cine. How this impacts on the development of services
in these different health care systems is beyond the
scope of this review but is an important question.
The implementation of genomic medicine across
the whole healthcare service has the potential to
signiﬁcantly increase the demand for clinically prac-
tising genetic counsellors. If, as predicted, hundreds
of thousands more patients have a genomic test as
part of their diagnostic pathway, any complications
from this will result in a post-results referral back
into clinical genetics. It will be genetic counsellors
who will likely pick up these referrals (having
expertise in explaining the signiﬁcance of genomic
results and help the patient make sense of these)
and also sort out the cascade family testing. For
every new genetic diagnosis made in a non-genetics
healthcare setting, the clinician who orders the test
and delivers the results, should have a conversation
about the impact of these for relatives. Given that
non-genetics clinicians would not routinely care for
at-risk, healthy relatives, the future management of
such ‘patients in waiting’ will be enabled by a referral
into tertiary genetic counselling services. Workforce
planning and the need for more skilled staff is recog-
nized as an issue that needs addressing both in the
UK and internationally. The genetic counselling work
force is integral to this.
Giving results and managing the
consequences
The large amount of data generated by genomic
technologies and the potential for uncertainty is a
feature of genetic testing in the genomic era. It has
been suggested that genomic medicine will feature
heavily on enabling patients to manage and adapt
to uncertainty.22
In the past, genetic services focussed on rare syn-
dromes and inherited genetic disorders. Families
with these types of conditions will still be a signiﬁ-
cant part of genomic medicine practice. The major-
ity of genomic testing used clinically to date is in
the diagnosis of single gene disorders. As discussed
previously, deﬁnitions of genetic counselling as a
client-centred communication process incorporate
an aim of adjustment and adaptation to the medical
or psychosocial consequences of genetic contribu-
tions to disease.12 It has been noted however that
the ‘teaching model’ within genetic counselling
practice, has become predominant with less time
being given to eliciting client concerns or providing
7Genetic counselling in the era of genomic medicine, 2018
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psychological care.37 There is a debate in the literature
as to whether the psychotherapeutic aspect of managing
genetic information should be made more prominent13
partly in response to acknowledging that all health care
professionals in the future will be having conversations
with their patients about genomic results. Such conver-
sation, whilst it might draw on good medical communi-
cation skills, is not genetic counselling and while health
care professionals may need support in delivering the
genomic information they will not be providing genetic
counselling per se. Genetic counselling attends to both
the educational component and the psychosocial and
emotional component of the genomic information and
incorporates discussion with relatives.8
There is evidence that genetic counselling can lead
to a range of positive outcomes including increased
knowledge, perceived personal control; positive risk
behaviours and improved risk perception.38 Genetic
counsellors have been engaged in research to develop
their practice and interventions to assist patients and
their families in managing the genetic information.39,40
However it is recognized that there is a need for greater
evidence base for genetic counselling in order that ser-
vices may continue to evolve to meet the changing
needs of patients and families with genetic conditions.10
In the same way that developing roles in laboratories
and variant interpretation are amenable to technology
solutions that assist in test selection or interpretation of
variants, the educational and information provision
aspect of genetic counselling may also lend itself to
innovative ways of delivery. For example in August
2017 a genetic testing company announced the
formation of a start-up company to develop an
internet algorithm (chatbot) to guide patients through
their genetic tests. However the provision of informa-
tion about tests and their potential results cannot ever
replace the psychosocial conversation, based on a two-
way, patient-led conversation that addresses the needs
of patients to adapt and adjust and incorporate this
new knowledge into their lives.
Genetic counselling in the era of
genomic medicine
Examination of the literature and discussions with
experts has demonstrated that genetic counsellors
are involved at all stages in the pathway of the
patient journey through genomic medicine. At the
beginning, with genetic risk estimation, decision-
making about testing and conversations about con-
sent; in the management and interpretation of
results; at the point at which the result enters into
the health care system and is returned to the clin-
ician and the patient, at the follow up of patients in
mainstream and in helping the patient to seek out
and communicate the results within their family.
Genetic counsellors are also involved in support-
ing the patient to adapt to the genetic informa-
tion and manage the psychosocial consequences
of this as it is relevant to the wider family and
future generations.
As genomic medicine develops it will become
clearer as to what aspects of genetic counselling will
become part of mainstreamed health services and
what aspects will remain within the domain of the
specialist genetics workforce. The current focus on
information provision prior to the test and man-
aging information generated by the genomic ana-
lysis may change as solutions are developed that
make this more routine. However, the consequences
of the genetic information, particularly as it relates
to conditions with implications for future health
and familial implications, may need more specialist
genetic counselling skills in order that patients and
families can adjust and adapt to the information
and use it effectively to maximize the health gains
from genomic medicine and minimize potential
harms.
In order to increase the evidence base for prac-
tice there is an urgent need for funding and research
resources to be focussed on implementation and
outcome research. This needs to explore how to
enable health care systems, practitioners, patients
and families to maximize the utility of the new
knowledge. Genetic counsellors with their experi-
ence of implementing genetic medicine should be at
the heart of effective and responsible implementa-
tion of genomic medicine.
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